Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Corticotropin-releasing factor (CRF)-like immunoreactivity was measured by radioimmunoassay in human organs and tumors associated with and without ectopic adrenocorticotropic hormone (ACTH) syndrome. It was found to be distributed widely in the stomach, pancreas, adrenal gland, and various tumors (e.g., medullary thyroid carcinoma, small cell carcinoma of the lung, pheochromocytoma, and adenocarcinoma of the gastrointestinal tract and pancreas) in a concentration less than one tenth of that of the hypothalamus. Dilution curves of CRF-like immunoreactivity in tissue extracts paralleled that of synthetic rat (human) CRF. Sephadex G-50 gel filtration showed that a major CRF-like immunoreactivity in tissue extracts coeluted with synthetic rat (human) CRF. Results suggest that a material(s) closely related immunologically to CRF is present widely in normal and tumor tissues outside of the central nervous system.
Cancer 1985 Mar 01
PMID:Presence of corticotropin-releasing factor-like immunoreactivity in human tumors. 387 47

Adrenal rest tumors of the testes may occur in conditions associated with increased circulating adrenocorticotropic hormone (ACTH), including congenital adrenal hyperplasia (CAH) and Addison disease. Sonographically, these tumors appear as multiple round, hypoechoic nodules near the testicular hilus and are usually bilateral. They may undergo extensive fibrosis and become hyperechoic with acoustic shadowing. In the absence of excess ACTH or characteristic ultrasound findings, biopsy is recommended to exclude malignancy. Because malignant degeneration is very rare, close clinical and sonographic follow-up without biopsy is generally sufficient. Serial sonograms are useful to document stability or regression of tumor size during glucocorticoid replacement therapy.
 ...
PMID:Intratesticular adrenal rests diagnosed by ultrasound. 388 14

A spontaneous cyclic phenomenon characterized by successive waves of either high proliferative rate or intense melanogenesis is described in non-confluent B16 melanoma cells subcultivated during 2 months (or more). Dopaoxidase activity is quantified in individual cells after L-dopa reaction, by an original method of visible light absorption cytophotometry. A 24-hr treatment with alpha-MSH increases dopa-oxidase activity. This increase is also noted during the following 14 hr, in a fresh medium devoid of alpha-MSH, in which cell proliferation resumes after 24 hr. Phenylthiourea, cycloheximide or actinomycin D inhibit dopaoxidase activity, but also cell proliferation in alpha-MSH pre-stimulated cells. The effects of the two latter agents suggest that de novo synthesis of the enzyme takes place following alpha-MSH treatment.
Eur J Cancer Clin Oncol 1985 Aug
PMID:Quantitative cytochemical analysis by microdensitometry of spontaneous or alpha-MSH-stimulated melanogenesis in B16 melanoma cells cultivated in vitro. 393 Feb 53

The antitumor action of the 2-chloroethylnitrosocarbamoyl derivatives of peptides related to the 9-13 amino acid residues of alpha-MSH/ACTH and of the C-terminal tetrapeptide analogue of gastrin have been investigated. Series of 2-chloroethylnitrosoureas attached to amino acids, di-, tri-, tetra-, or pentapeptides were examined in a primary screening system. Among these compounds the Pro-Val-, Lys-Pro-Val-, and Trp-Gly-Lys-Pro-Val-containing 2-chloroethylnitrosocarbamoyl groups were the most effective in the L1210 system. The human melanoma xenograft line was also affected by these agents, while colorectal xenografts were insensitive. A combination of tripeptide-2-chloroethyl-nitrosourea with BCNU induced more than additive growth inhibition of L1210 leukemia.
Cancer Chemother Pharmacol 1986
PMID:Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments. 394 98

Fifty-five adenomas were identified and characterized in the anterior pituitaries of 27 male and 39 female SD rats, over 24 months of age, by histology, ultrastructural morphology, and immunocytochemistry. Adenomas were found in 85% of male and 79% of female rats; all known adenohypophysial hormones were represented in various tumors. Prolactin (PRL)-containing adenomas were the most common (47.2%); luteinizing hormone-(LH)-containing adenomas (16.3%), immunonegative adenomas (12.7%), PRL- and growth hormone (GH)-containing adenomas (10.9%), thyroid-stimulating hormone (TSH)-containing adenomas (3.6%), adrenocorticotropin hormone (ACTH)-containing adenomas (3.6%), and GH-containing adenomas (1.8%) were also identified. Unexpected combinations were observed in 3 tumors (5.4%); a GH-LH-containing adenoma, a PRL-ACTH-containing adenoma, and a PRL-LH-TSH-containing adenoma were noted. One intermediate lobe adenoma and 1 metastatic plasmacytoma were diagnosed. It can be concluded that spontaneous pituitary adenomas in aging SD rats are potential models of the human disease because of diversity of hormone content and morphologic appearance.
J Natl Cancer Inst 1984 Nov
PMID:Pituitary adenomas in old Sprague-Dawley rats: a histologic, ultrastructural, and immunocytochemical study. 609 68

Profound and long-lasting analgesia (mean duration of pain relief 33.4 h, range 22.5--73.5 h) was produced by intrathecal administration of 3 mg synthetic beta-endorphin in all of 14 patients with intractable pain due to disseminated cancer. No respiratory depression, hypotension, hypothermia, or catatonia was observed.
 ...
PMID:Profound analgesic effects of beta-endorphin in man. 610 59

Due to recent interest in the development of drug assay techniques, the pharmacokinetics of many analgesics have been defined. In addition, mechanisms of action of the commonly used analgesics have been partly delineated, and currently accepted analgesic regimens and usages are being questioned. By considering both the pharmacokinetics and the mechanism of action of each of these analgesics, it would appear that only a few of the currently available agents are needed for the treatment of acute and chronic pain. Newer agents with reduced toxicity have been introduced but have resulted in little expansion of novel ways to interfere with pain. The recent discovery of the beta-endorphin system, the reevaluation of older agents, and the development of new agents that work at pain pathways other than the classical sites hold out the promise of alternative means of control of certain types of pain. An agent that has analgesic efficacy equivalent to morphine but with reduced toxicity is especially exciting in the development of new analgesics. An agent that, in addition, does not lead to intolerable psychomimetic reactions but instead addresses multiple aspects of treating the fear, pain, and tension triad of pain will be beneficial in acute pain but will especially enhance the spectrum of the control of chronic pain such as cancer, neuralgia and arthralgia.
 ...
PMID:Pharmacokinetics and mechanisms of action of analgesics in clinical pain. 611 74

Eighty-one primary ovarian carcinoids and intraovarian metastases from six mid-gut carcinoids were examined for the presence of tumor cells immunoreactive with antisera raised against various neurohormonal peptides, mostly of gastroenteropancreatic (GEP) origin. Twenty of the primary and two of the metastatic carcinoids contained such tumor cells. The incidence of tumors with any kind of neurohormonal peptide immunoreactive tumor cells was 53% in the trabecular carcinoids, and 42% in the strumal carcinoids, whereas the incidence was much lower (7%) in the insular type. Immunoreactive pancreatic polypeptide (PP), glucagon, enkephalin, and somatostatin were those neurohormonal peptides most commonly observed in the tumor cells of the primary carcinoids. Those less commonly found were substance P, calcitonin, VIP, neurotensin, beta-endorphin, and ACTH. Four metastatic carcinoids were nonreactive with all the antisera used. Cells storing immunoreactive insulin, glucagon, PP, VIP, gastrin, substance P, or enkephalin were found in one of the two remaining metastatic carcinoids; in the other only gastrin-immunoreactive tumor cells were observed. The occurrence and distribution of tumor cells storing the neurohormonal peptides in ovarian carcinoids are discussed in relation to their possible origin in the ovary and to carcinoids in the gut.
Cancer 1982 Jan 01
PMID:Neurohormonal peptides in ovarian carcinoids: an immunohistochemical study of 81 primary carcinoids and of intraovarian metastases from six mid-gut carcinoids. 611 50

Twenty-five endocrine tumors of the rectum (rectal carcinoids) were examined immunohistochemically for various pancreatic and gut neurohormonal polypeptides. Twenty-one of the tumors were found to contain cells displaying pancreatic polypeptide (PP), glucagon, somatostatin, insulin, substance P, enkephalin or beta-endorphin immunoreactivity. At least 11 of the tumors contained more than one peptide hormone. In some of the tumors PP cells made up the major cell population, in others the glucagon cells constituted the majority. Only four of the tumors contained 5-hydroxytryptamine. Rectal endocrine tumors seem unique among gut endocrine tumors in that they may store immunoreactive enkephalin, beta-endorphin and even insulin. None of the patients displayed the carcinoid syndrome; symptoms were usually vague and uncharacteristic. In many cases the tumor was found at routine examination.
Cancer 1981 Dec 01
PMID:Immunohistochemical evidence of peptide hormones in endocrine tumors of the rectum. 617 Apr 21

In oat cell (small cell) carcinoma and, to some extent, in other histological types of lung cancer, improved forms of treatment have resulted in prolongation of survival and even cure. Progress is hampered by the lack of reliable biochemical markers such as those which have completely changed the management and outlook in testicular and gestational carcinoma. Carcinoembryonic antigen (CEA) has been of some value. Raised circulating levels of calcitonin and of adrenocorticotropic hormone (ACTH) are found in many patients with lung cancer but have not proved as useful for monitoring disease progression. It is probable that since lung tumors form a heterogeneous population, production of markers varies with histological type. Our approach has been to affinity purify those polyclonal antisera to potential lung tumor markers which are not yet available as monoclonal hybridoma antibodies and to examine 10 representative resection specimens of each of the four common carcinoma types--squamous, adeno-, large cell, and small cell using an indirect immunoperoxidase localization technique on formalin-fixed paraffin-embedded sections. Substances localized included CEA, epithelial membrane antigen, calcitonin, alpha and beta subunits of human chorionic gonadotropin, and human placental lactogen.
Cancer Detect Prev 1982
PMID:Biological markers in lung cancer: an immunocytochemical approach. 618 9


<< Previous 1 2 3 4 5 6 7 8 9 10